We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+10.71%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$4.15M
Cap. Flow
-$8.23M
Cap. Flow %
-7.12%
Top 10 Hldgs %
50.71%
Holding
66
New
3
Increased
–
Reduced
29
Closed
2

Top Buys

Rank Stock Value
1
PRQR icon
ProQR Therapeutics
PRQR
+$1.1M
2
KYNB
Kyntra Bio
KYNB
+$222K

Top Sells

Rank Stock Value
1
LABU icon
Direxion Daily S&P Biotech Bull 3X ETF
LABU
+$1.37M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$552K
3
NKTR icon
Nektar Therapeutics
NKTR
+$483K
4
JUNO
Juno Therapeutics, Inc.
JUNO
+$456K
5
NBIX icon
Neurocrine Biosciences
NBIX
+$371K

Sector Composition

Rank Sector Weight
1 Healthcare 67.33%
2 Miscellaneous 32.4%
3 Real Estate 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRFS
51
Grifois
GRFS
$5.32B
$265K 0.23%
11,565
-13,240
-53% -$294K
TECH icon
52
Bio-Techne
TECH
$11.4B
$257K 0.22%
7,948
-9,124
-53% -$290K
JUNO
53
DELISTED
Juno Therapeutics, Inc.
JUNO
$255K 0.22%
5,588
-9,132
-62% -$456K
CRL icon
54
Charles River Laboratories
CRL
$14.2B
$236K 0.2%
2,154
-2,801
-57% -$305K
IQV icon
55
IQVIA
IQV
$43.2B
$236K 0.2%
2,415
-2,998
-55% -$305K
SCTL
56
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$233K 0.2%
28,133
– –
ICPT
57
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$221K 0.19%
3,779
-702
-16% -$44.3K
GILD icon
58
Gilead Sciences
GILD
$185B
$220K 0.19%
3,075
-3,387
-52% -$257K
KYNB
59
Kyntra Bio
KYNB
$32.4M
$210K 0.18%
+177
New +$222K
ACAD icon
60
Acadia Pharmaceuticals
ACAD
$5.12B
$207K 0.18%
6,880
-8,759
-56% -$280K
PGEN icon
61
Precigen
PGEN
$2.57B
$164K 0.14%
14,221
-9,707
-41% -$145K
SCYX icon
62
SCYNEXIS
SCYX
$54.9M
$155K 0.13%
833
– –
CFRX
63
DELISTED
ContraFect Corporation
CFRX
$152K 0.13%
188
– –
PGNX
64
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$130K 0.11%
21,782
– –
LABU icon
65
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$720M
– –
-800
Closed -$1.37M
LGND icon
66
Ligand Pharmaceuticals
LGND
$5.67B
– –
-2,435
Closed -$207K
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q4 2017 Portfolio in Review

As of Q4 2017, Opus Point Partners Management held 66 positions worth $116M, up 3.7% from $111M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Opus Point Partners Management withdrew a net $8.23M in Q4 2017, closing 2 positions and reducing 29 holdings. Its most notable exit was Direxion Daily S&P Biotech Bull 3X ETF, an estimated $1.37M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 74% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Opus Point Partners Management opened a new position in ProQR Therapeutics worth $992K.

  • Opus Point Partners Management's largest Q4 2017 buy was ProQR Therapeutics: 307,692 shares worth $992K.
  • Opus Point Partners Management's biggest Q4 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $552K.
  • Opus Point Partners Management fully exited Direxion Daily S&P Biotech Bull 3X ETF in Q4 2017, selling an estimated $1.37M.
  • Opus Point Partners Management's ten largest holdings make up 51% of its $116M portfolio in Q4 2017.
  • Opus Point Partners Management opened 3 new positions and closed 2 in Q4 2017.
  • Opus Point Partners Management's portfolio value rose 3.7% quarter-over-quarter to $116M.

Based on Opus Point Partners Management's 13F filing for Q4 2017, filed 14 Feb 2018.